 |
BioWorld-International-2011-01-19
Symphogen Round Is 'Not Typical'; Funding Hard to Find
Symphogen Round Is 'Not Typical'; Funding Hard to Find
LONDON – The $131 million raised by Symphogen A/S earlier this month – the the largest private financing ever for a European biotech – will be a boost for the sector in Denmark, but it does not mean the funding climate in Europe is improving.
Domain Inks $180M Early Stage GPCR Deal with Merck Serono
LONDON – Domain Therapeutics SA sealed a collaboration potentially worth €134 million (US$179.6 million) plus royalties for a discovery-stage program targeting a G protein-coupled receptor (GPCR) implicated in Parkinson's and other neurodegenerative diseases. (BioWorld International)